Science Corporation

“The two leading causes of death though, are cardiovascular disease and cancer is not metastasized to the brain. And I think both of those are going to be really attackable through this type of work.”

“I mean, in the clinical trial, I mean, the main thing was just the existence proof of like that success was a possible outcome, right? Like that we had patients filling in Sudoku puzzles or crossword puzzles. There were patients that were reading books.”

“So we mostly raised from tech investors, not that much from biotech investors. In fact, there's only one VC that I sought out at all at the Series A that I went to go pitch, which was Bob Nelson, who's a biotech investor.”

“We think we see a path to get at least red and green. Blue is a little bit trickier.”

“Through a mix of the BCIs that allow you to kind of change the system, the thing that it's interacting with and our perfusion medicine program we think that there's ways to significantly improve not just lifespan, but healthspan and kind of create a better qua…”

“The, at the other end of that spectrum are things like generating vision or generating hearing or achieving substrate independence. Those are the things that we are focused on, not brain keyboard.”

“So there's three elements to our pipeline. The first is our work in vision. Second is our bio hybrid neural interfaces. And the third is that our work in a different area of medicine perfusion, a program called vessel.”

“Nobody had previously ever been able to restore a form vision image in the mind's eye of a blind patient in this way.”